Integrating EPA-based therapy in the management of residual CV risk10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Paris, France - Online CME
Video navigation menu
- Residual CV risk and TG 0:34
- Trials with omega-3 FAs 2:02
- Icosapent ethyl and generalizability of REDUCE-IT 4:56
- Additional observations with high dose EPA 6:30
- Conclusions 8:12
This lecture by prof. Gabriel Steg was part of an accredited symposium "Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides" held during the virtual ESC Congress 2021.
Gabriel Steg is professor at the Department of Cardiology in the Hôpital Bichat, Paris, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant received from Amarin.
This is available as accredited online CME for members. Click the button below to enroll:Enroll
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: